Engineered cross‐reacting nanobodies simplify comparative oncology between humans and dogs

Mazzega, Elisa; Marco, Ario de

doi:10.1111/vco.12359

Cited by 8 publications

(3 citation statements)

References 30 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognition of HER2 and DER2 was evaluated by flow cytometry and IFA to detect breast cancer cells from humans (SKBR3) and dogs (SH1B and P114). Therefore, these rAbs can be used to identify malignant cells and have the potential to be used as immunotherapeutics in dogs and humans ( 28 ).…”

Section: Recombinant Antibodies In Veterinary Diagnosismentioning

confidence: 99%

Recombinant Antibodies in Veterinary Medicine: An Update

2018

View full text Add to dashboard Cite

The production of recombinant antibodies has had a tremendous impact on several research fields, most prominently in biotechnology, immunology and medicine, enabling enormous advances in each. Thus far, a broad diversity of recombinant antibody (rAb) forms have been designed and expressed using different expression systems. Even though the majority of rAbs approved for clinical use are targeted to humans, advances in veterinary medicine seem promising. The aim of this mini-review is to present an update regarding the rAbs in veterinary medicine reported to date, as well as their potential use in diagnostics, prophylaxis and therapeutics. Full- and single-chain fragment variables are the most common forms of rAbs developed for the detection, prevention and control of parasitic, bacterial and viral diseases, as well as pain and cancer treatment. Nonetheless, advances in research seem to be skewed toward economically important animals, such as pigs, cows, poultry and dogs. Although significant results have been obtained from the rAbs reported here, most have not been developed enough to be approved. Further research and clinical trials should be encouraged to enable important findings to fulfill their intended potential to improve animal well-being.

show abstract

Section: Recombinant Antibodies In Veterinary Diagnosismentioning

confidence: 99%

Recombinant Antibodies in Veterinary Medicine: An Update

2018

View full text Add to dashboard Cite

show abstract

“… 40 Therefore, we decided to explore the short H6 tag, fused to nanobodies and GFP ( Figure 1 B), as a tool to generate large self-assembled multivalent and multifunctional nanoparticles. For that, two unrelated nanobodies were selected as models, namely A3C8, specific for ricin toxin, and EM1, specific for Her2 ( Figure 1 C), 41 , 42 and engineered to demonstrate the feasibility of the proposed approach, that is, controlled oligomerization into nanoparticles while preserving functionalities of the nanobodies and of other incorporated protein domains.…”

Section: Introductionmentioning

confidence: 99%

Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials

Sánchez‐García

Voltà‐Durán

Parladé

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Nanobodies represent valuable tools in advanced therapeutic strategies but their small size (∼2.5 × ∼ 4 nm) and limited valence for interactions might pose restrictions for in vivo applications, especially regarding their modest capacity for multivalent and cooperative interaction. In this work, modular protein constructs have been designed, in which nanobodies are fused to protein domains to provide further functionalities and to favor oligomerization into stable self-assembled nanoparticles. The nanobody specificity for their targets is maintained in such supramolecular complexes. Also, their diameter around 70 nm and multivalent interactivity should favor binding and penetrability into target cells via solvent-exposed receptor. These concepts have been supported by unrelated nanobodies directed against the ricin toxin (A3C8) and the Her2 receptor (EM1), respectively, that were modified with the addition of a reporter protein and a hexa-histidine tag at the C-terminus that promotes self-assembling. The A3C8-based nanoparticles neutralize the ricin toxin efficiently, whereas the EM1-based nanoparticles enable to selective imaging Her2-positive cells. These findings support the excellent extracellular and intracellular functionality of nanobodies organized in form of oligomeric nanoscale assemblies.

show abstract

“…In terms of tumour treatment, advantage was taken of high similarity between human epidermal growth factor receptor and its canine homologue and two recombinant antibodies with crossreactivity generated; both seemed suitable for detection of malignant cells when tested to detect breast cancer cells (132).…”

Section: Bovine Recombinant Antibodies Have Been Developed For Diagno...mentioning

confidence: 99%

Construction of an equine antibody library in the single-chain-Fragment-variable format (scFv) to express equine immunoglobulins

Franziska¹

View full text Add to dashboard Cite

show abstract

Engineered cross‐reacting nanobodies simplify comparative oncology between humans and dogs

Cited by 8 publications

References 30 publications

Recombinant Antibodies in Veterinary Medicine: An Update

Recombinant Antibodies in Veterinary Medicine: An Update

Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials

Construction of an equine antibody library in the single-chain-Fragment-variable format (scFv) to express equine immunoglobulins

Contact Info

Product

Resources

About